IP Library › Granted Patent US 8,445,426
Granted Patent B2
US 8,445,426 · App. 12/364,128 · Granted May 21, 2013

Peptides and methods for producing them

Inventors: Willem Meindert De Vos (Ede, NL); Airi Palva (Helsinki, FI); Ilkka Palva (Helsinki, FI); Justus Reunanen (Kerava, FI); Ingemar Von Ossowski (Helsinki, FI); Reetta Satokari (Kirjala, FI); Satu Vesterlund (Naantali, FI); Matti Kankainen (Helsinki, FI); Tuomas Salusjärvi (Espoo, FI); Soile Tynkkynen (Helsinki, FI)
Assignee: Valio Ltd.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,445,426
App. No.
12/364,128
Granted
May 21, 2013
Kind
B2
Abstract

The present invention relates to the fields of life sciences and food, feed or pharmaceutical industry. Specifically, the invention relates to novel peptides, pilus structures, polynucleotides as well as vectors, host cells, products and pharmaceutical compositions comprising the polynucleotides, peptides or pilus structures. The invention also relates to gene clusters and antibodies. Furthermore, the present invention relates to methods for producing the peptides or pilus structures or producing the products comprising the peptides or pilus structures. Furthermore, the present invention relates to treatments as well as uses and methods for screening bacterial strains, for reducing or inhibiting the adhesion of pathogenic bacteria, promoting the adhesion of bacterial cells to the mucus and for modifying immune response in a subject. Still, the present invention relates to methods for detecting probiotic bacterial strains or pathogen strains.

Claims (16)

1. An isolated peptide comprising a sequence having at least 94% sequence identity with SEQ ID NO: 4 (GG00444).

2. The peptide according to claim 1 , which is a recombinant peptide.

3. The peptide according to claim 1 , which is from bacteria.

4. The peptide according to claim 3 , which is from Lactobacillus rhamnosus.

5. The peptide according to claim 4 , which is from Lactobacillus rhamnosus GG (LGG) strain.

6. The peptide according to claim 1 , which binds to the gastrointestinal tract.

7. The peptide according to claim 1 , which binds to the mucus.

8. A product comprising the peptide according to claim 1 .

9. The product according to claim 8 , which is a food or feed product.

10. The food product according to claim 9 , wherein the food product is selected from the group consisting of a dairy products, a bakery product, a chocolate, a confectionary, a sugar confectionary, a gum confectionary, a cereal product, a snack, a berry based product, a fruit based product, a drink and a beverage.

11. The food product according to claim 10 , wherein the food product is selected from the group consisting of a milk product, a sour milk product, a yogurt, a cheese, a spread, a milk powder, a children's food, a baby food, a toddler's food, an infant formula, a juice and a soup.

12. A pharmaceutical composition comprising the peptide according to claim 1 .

13. A method of treating a disorder selected from the group consisting of diarrhea, arterial hypertension, vascular disease, allergy, cancer, atopic disease, viral disease, infectious disease, urinary tract infection, respiratory infection, dental caries, irritable bowel syndrome, inflammatory bowel disease, mucosal inflammation, gut permeability disorder, obesity, metabolic syndrome, oxidative stress and abdominal pain in a subject in need thereof, comprising administering the peptide of claim 1 to the subject.

14. A method of reducing or inhibiting the adhesion of pathogenic bacteria to the gastrointestinal tract, to the epithelium or to the mucus of a subject, comprising administering the peptide according to claim 1 to the subject.

15. The peptide according to claim 1 comprising a sequence having at least 95% sequence identity with SEQ ID NO:4 (GG00444).

16. The peptide according to claim 1 , which is a purified peptide.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2017
From: VALIO LTD.
To: CHR. HANSEN A/S
Reel/Frame 042272/0897 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2009
From: MEINDERT DE VOS, WILLEM; PALVA, AIRI; PALVA, ILKKA; REUNANEN, JUSTUS; VON OSSOWSKI, INGEMAR; SATOKARI, REETTA; VESTERLUND, SATU; KANKAINEN, MATTI; SALUSJARVI, TUOMAS; TYNKKYNEN, SOILE
To: VALIO LTD.
Reel/Frame 022591/0823 →
Continuity (1)
Related Publication 20100196524A1 · Aug 5, 2010